Kliniske studier for Migrene i Illinois
6 studier for Migrene søker deltakere på steder i Illinois.
Byer i Illinois
Offisiell studietekst (engelsk)
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
- Chicago Headache Center & Research Institute, Chicago
- AMR-Baber Research Inc, Naperville
RekruttererFase 3
Alder 6 til 17 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT04743141Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- Chicago Headache Center & Research Institute, Chicago
- AMR-Baber Research Inc, Naperville
RekruttererFase 3
Alder 6 til 17 · Alle kjønn · Oppdatert 24. sep. 2026 · NCT04649242Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Chicago Headache Center & Research Institute /ID# 248625, Chicago
- Ascension Saint Alexius /ID# 275261, Hoffman Estates
RekruttererFase 3
Alder 6 til 17 · Alle kjønn · Oppdatert 14. sep. 2026 · NCT05125302A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Cedar Crosse Research Center, Chicago
- Chicago Headache Center & Research Institute, Chicago
- Healthcare Research Network II, LLC, Flossmoor
- og 1 flere
RekruttererFase 3
Alder 18 til 75 · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07645924Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
- Chicago Headache Center & Research Inst /ID# 272345, Naperville
RekruttererObservasjonsstudie
Alder 18 og eldre · Alle kjønn · Oppdatert 10. feb. 2026 · NCT07310290Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines
- Advocate Christ Medical Center Emergency Department, Oak Lawn
RekruttererFase 3
Alder 18 og eldre · Alle kjønn · Oppdatert 22. jan. 2026 · NCT06904287Fra ClinicalTrials.gov, data hentet 4. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.